Literature DB >> 18293201

Prostacyclin and thromboxane levels in women with severe preeclampsia undergoing magnesium sulfate therapy during antepartum and postpartum periods.

Yuping Wang1, Yanping Zhang, Bernard J Canzoneri, Yang Gu, Lisa Philibert, David F Lewis.   

Abstract

OBJECTIVE: To study effects of magnesium sulfate (MgSO(4)) on prostacyclin (PGI(2)) and thromboxane A(2) (TXA(2)) levels in women with severe preeclampsia during antepartum and postpartum periods.
METHODS: Women with severe preeclampsia were randomized into two groups. Patients in Group A were continuously infused with MgSO(4) for 24 hours postpartum. In Group B, MgSO(4) administration was discontinued when urinary output was of > or =100 ml/hr for 2 consecutive hours. Patient demographic data were collected. Venous blood was drawn at time of MgSO(4) administration and 24 hours after delivery. Plasma levels of 6-keto-PGF1alpha and TXB(2), stable metabolites of PGI(2) and TXA(2), were measured by enzyme-linked immunosorbent assay (ELISA). Data are presented as mean +/- SE, and analyzed by paired t-test.
RESULTS: A total of 50 patients were recruited, with 27 in Group A and 23 in Group B. There were no statistical differences for demographic data between the two groups with regards to maternal age; gestational age; systolic and diastolic blood pressures at admission, 12 hours postpartum, and 24 hours postpartum; and mode of delivery. Platelet counts were all within the normal range at the time of enrollment. MgSO(4) was administered for an average of 10 hours postpartum in Group B. Maternal blood pressures returned to normal or close to normal levels in both groups at 24 hours postpartum. 6-keto PGF1alpha levels were significantly decreased 24 hours after delivery compared with the levels at enrollment in both groups, (Group A: 98 +/- 13 vs. 180 +/- 28 pg/mL; Group B: 142 + 17 vs. 194 +/- 31 pg/mL, p < 0.05, respectively). However, there was no difference detected between the two groups. TXB(2) levels were not different between group A and Group B at the time of enrollment, 38 +/- 9 vs. 33 +/- 8 pg/mL, and 24 hours postpartum, 26 +/- 5 vs. 25 +/- 3 pg/mL, respectively.
CONCLUSIONS: Administration of MgSO(4) does not affect prostacyclin and thromboxane levels in the maternal circulation in women with preeclampsia during antepartum and postpartum periods. We speculate that a higher level of prostacyclin before delivery may reflect compensatory effects of this vasodilator to offset increased maternal blood pressure during pregnancy.

Entities:  

Mesh:

Substances:

Year:  2008        PMID: 18293201      PMCID: PMC3070486          DOI: 10.1080/10641950701825721

Source DB:  PubMed          Journal:  Hypertens Pregnancy        ISSN: 1064-1955            Impact factor:   2.108


  15 in total

1.  Mechanisms involved in the antiplatelet activity of magnesium in human platelets.

Authors:  Joen-Rong Sheu; George Hsiao; Ming-Yi Shen; Tsorng-Harn Fong; Yi-Win Chen; Chien-Huang Lin; Duen-Suey Chou
Journal:  Br J Haematol       Date:  2002-12       Impact factor: 6.998

2.  Prostacyclin and pre-eclampsia.

Authors:  P J Lewis; G L Shepherd; J Ritter; S M Chan; P J Bolton; M Jogee; L Myatt; M G Elder
Journal:  Lancet       Date:  1981-03-07       Impact factor: 79.321

3.  Reduced prostacyclin production in pre-eclampsia.

Authors:  I Downing; G L Shepherd; P J Lewis
Journal:  Lancet       Date:  1980 Dec 20-27       Impact factor: 79.321

4.  Population pharmacokinetics of magnesium in preeclampsia.

Authors:  F S Chuan; B G Charles; R K Boyle; R L Rasiah
Journal:  Am J Obstet Gynecol       Date:  2001-09       Impact factor: 8.661

5.  The effect of magnesium sulfate infusion on systemic and renal prostacyclin production.

Authors:  W F O'Brien; M C Williams; R Benoit; S K Sawai; R A Knuppel
Journal:  Prostaglandins       Date:  1990-11

Review 6.  Diagnosis and management of gestational hypertension and preeclampsia.

Authors:  Baha M Sibai
Journal:  Obstet Gynecol       Date:  2003-07       Impact factor: 7.661

7.  Magnesium sulfate: rationale for its use in preeclampsia.

Authors:  K V Watson; C F Moldow; P L Ogburn; H S Jacob
Journal:  Proc Natl Acad Sci U S A       Date:  1986-02       Impact factor: 11.205

8.  Do women with pre-eclampsia, and their babies, benefit from magnesium sulphate? The Magpie Trial: a randomised placebo-controlled trial.

Authors:  Douglas Altman; Guillermo Carroli; Lelia Duley; Barbara Farrell; Jack Moodley; James Neilson; David Smith
Journal:  Lancet       Date:  2002-06-01       Impact factor: 79.321

9.  A comparison of magnesium sulfate and nimodipine for the prevention of eclampsia.

Authors:  Michael A Belfort; John Anthony; George R Saade; John C Allen
Journal:  N Engl J Med       Date:  2003-01-23       Impact factor: 91.245

10.  Maternal plasma prostacyclin concentration in pre-eclampsia and other pregnancy complications.

Authors:  O Ylikorkala; P Kirkinen; L Viinikka
Journal:  Br J Obstet Gynaecol       Date:  1981-10
View more
  2 in total

Review 1.  Magnesium sulphate and other anticonvulsants for women with pre-eclampsia.

Authors:  Lelia Duley; A Metin Gülmezoglu; David J Henderson-Smart; Doris Chou
Journal:  Cochrane Database Syst Rev       Date:  2010-11-10

Review 2.  Alternative magnesium sulphate regimens for women with pre-eclampsia and eclampsia.

Authors:  Lelia Duley; Hosam E Matar; Muhammad Qutayba Almerie; David R Hall
Journal:  Cochrane Database Syst Rev       Date:  2010-08-04
  2 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.